title: [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration].
abstract: Potential weight gain must be taken into account in the patient's comprehensive treatment approach when initiating antipsychotic treatment with Olanzapine. There are effective preventive and therapeutic pharmacological interventions to control this adverse effect. Not addressing this eventual treatment aspect of Olanzapine treatment may compromise the patient's health and his/her compliance with the pharmacological treatment indicated in serious psychiatric conditions. The decision to use a molecule must be made taking into account its efficacy, efficiency and adverse effect profile. In this study, concomitant administration of Ranitidine prevented or corrected weight gain in 59.6% of cases. Patients followed by 16 weeks had shown the following results: Olanzapine without Ranitidine, exhibited an average weight gain of 3.4 kilograms, ranging between -2.5 and +16 kg. This implies an average increase of 1.19 in BMI for this group. Patients treated additionally with Ranitidine at doses of 300 mg, a 0.9 kilogram weight gain ranging between -4 and +10.6 kg was observed, implying an average BMI change of 0.34. In patients treated with Ranitidine at doses of 600 mg, the weight gain curve trended toward normalization with a 1.6 kilogram decrease, ranging between -15 and +7 kilograms, accounting for a decrease of 0.6 points in BMI. While more extensive studies are required, our interest with this study is to demonstrate that we can count on a potentially simple and useful response for the treatment of weight gain associated with Olanzapine use. The risk/benefit ratio is a paradigm in the practice of medicine. In the case of Olanzapine, the scale clearly tips in favor of the latter, making it the drug of choice in the treatment of schizophrenia and other psychotic disorders.
authors.affiliation: Instituto de Psiquiatría Biológica Integral, Buenos Aires, Argentina. ipbi@arnet.com.ar
authors.forename: Andrea
authors.initials: A
authors.lastname: López-Mato
authors.forename: Javier
authors.initials: J
authors.lastname: Rovner
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Illa
authors.forename: Alejandra
authors.initials: A
authors.lastname: Vieitez
authors.forename: Oscar
authors.initials: O
authors.lastname: Boullosa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015992:Body Mass Index; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced* / Q000188:drug therapy*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D006635:Histamine H2 Antagonists; D001569:Benzodiazepines; D010890:Pirenzepine; D011899:Ranitidine; D000077152:Olanzapine